Remove Engineer Remove In-Vitro Remove Protein
article thumbnail

Aevitas to sell sCFH asset rights to 4D Molecular

Pharmaceutical Technology

sCFH is an engineered and improved version of complement factor H (CFH) that can fit into adeno-associated virus (AAV) vectors with solid expression and applications confirmed in cultured human cells in vitro, in addition to various preclinical animal models in vivo.

In-Vivo 130
article thumbnail

Pneumagen raises £8 million for further study of intranasal antiviral

Pharmaceutical Technology

Neumifil consists of an engineered carbohydrate-binding module domain of a Streptococcus pneumoniae protein. In April 2020, Pneumagen announced positive anti-viral activity results from three in vitro studies into preventing coronavirus infections, but the program has not yet been studied in humans. million ($4.75

In-Vitro 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Artificial Intelligence innovation: Leading companies in in-silico drug discovery

Pharmaceutical Technology

Innovation S-curve for artificial Intelligence in the pharmaceutical industry In-silico drug discovery is a key innovation area in artificial Intelligence Drug research starts with the discovery stage that involves in vivo and in vitro models to shortlist lead drug compounds.

Drugs 189
article thumbnail

A protein-based COVID-19 vaccine that mimics the shape of the virus

The Pharma Data

Food and Drug Administration were based on mRNA, more conventional protein-based vaccines have also shown promise in clinical trials. Most train the immune system to recognize the RBD, a peptide that is the portion of the SARS-CoV-2 spike protein that binds to the ACE-2 receptor on host cell surfaces.

Protein 52
article thumbnail

Twin Firsts for Tecelra — First Engineered Cell Therapy for Solid Tumors and First New Treatment in a Decade for Synovial Sarcoma

XTalks

Tecelra is the first cell therapy engineered for a solid tumor cancer in the US, offering a new option for patients with specific genetic markers who have previously undergone chemotherapy. Tecelra works by using the patient’s own immune system to target tumors expressing the melanoma-associated antigen A4 (MAGE-A4) protein on cancer cells.

article thumbnail

6th Annual 3D Cell Culture Conference

pharmaphorum

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Billion by 2028. Billion by 2028. Event Hashtag: #3DCellCulture2023.

article thumbnail

SMi’s 5th Annual 3D Cell Culture Virtual Conference

pharmaphorum

Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. Key Benefits of Attending: • Discuss the uses of advanced cell technologies to construct in vitro models of human tissues. Workshop Leader: Kenny Dalgarno, Professor of Manufacturing Engineering, Newcastle University. Who Should Attend?